Evaluation of high-grade astrocytoma recurrence patterns after radiotherapy in the era of temozolomide: A single institution experience

Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology
Arno Lotar CordovaValeriy Denyak

Abstract

Evaluating the recurrence patterns of high-grade astrocytomas in patients who were treated with radiotherapy (RT) plus temozolomide (TMZ). The current literature suggests that reducing the margins added to the CTV does not significantly change the risk of recurrence and overall survival; thus, we decided to analyze our data and to examine the possibility of changing the adopted margins. From February 2008 till September 2013, 55 patients were treated for high-grade astrocytomas, 20 patients who had been confirmed to have recurrence were selected for the present study. Post-operative MRI was superimposed on the planning CT images in order to correlate the anatomical structures with the treatment targets. Recurrences were defined according to the Response Assessment Criteria for Glioblastoma. The mean margins of the PTVinitial and PTVboost were 1.2 cm and 1.4 cm, respectively. The analysis of the percentage of the recurrence volume (Volrec) within the 100% isodose surface was based on the following criteria: (I) Central: >95% of the Volrec; (II) In-field: 81-95% of the Volrec; (III) Marginal: 20-80% of the Volrec; and (IV) Outside: <20% of the Volrec. Of the 20 patients, 13 presented with central recurrences, 3 with in-field recu...Continue Reading

References

Jan 11, 1992·International Journal of Radiation Oncology, Biology, Physics·L E GasparJ G Cairncross
Feb 16, 1999·International Journal of Radiation Oncology, Biology, Physics·S W LeeH M Sandler
Sep 7, 2000·The Journal of Comparative Neurology·T D PalmerF H Gage
Sep 8, 2001·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·H AydinH von Lieven
Nov 22, 2001·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·J Chavaudra, A Bridier
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Feb 20, 2007·International Journal of Radiation Oncology, Biology, Physics·Eric L ChangMoshe H Maor
Oct 13, 2007·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Kaveh Barami
Dec 12, 2007·British Journal of Neurosurgery·M D JenkinsonT S Smith
Dec 23, 2008·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Kaveh BaramiSteven Brem
Feb 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alba A BrandesMario Ermani
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Soonmee Cha
Mar 9, 2010·International Journal of Radiation Oncology, Biology, Physics·Michael T MilanoDavid N Korones
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Apr 20, 2010·International Journal of Radiation Oncology, Biology, Physics·Mark W McDonaldIan R Crocker
Jul 4, 2012·Neurosurgery Clinics of North America·Yasuaki Harasaki, Allen Waziri
Jun 6, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Komal AnjumSyed Shams Ul Hassan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.